Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
23,597,628
-
Total 13F shares
-
1,356,571
-
Share change
-
+1,356,571
-
Total reported value
-
$3,214,622
-
Price per share
-
$2.37
-
Number of holders
-
16
-
Value change
-
+$3,214,622
-
Number of buys
-
16
Institutional Holders of Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) as of Q4 2022
As of 31 Dec 2022,
Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,356,571 shares.
The largest 10 holders included
Alerce Investment Management, L.P., BVF INC/IL, VANGUARD GROUP INC, BLAIR WILLIAM & CO/IL, GEODE CAPITAL MANAGEMENT, LLC, KCK LTD., RENAISSANCE TECHNOLOGIES LLC, ADVISOR GROUP HOLDINGS, INC., UBS Group AG, and Tower Research Capital LLC (TRC).
This page lists
16
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.